Published in

Royal Society of Chemistry, Biomaterials Science, 4(6), p. 893-900

DOI: 10.1039/c8bm00106e

Links

Tools

Export citation

Search in Google Scholar

Adaptive immune cells are necessary for the enhanced therapeutic effect of sorafenib-loaded nanoparticles

Journal article published in 2018 by Zhi-Bin Zhao, Jie Long, Yang Zhao, Jing-Bo Yang, Wei Jiang, Qing-Zhi Liu, Kai Yan, Liang Li ORCID, Yu-Cai Wang ORCID, Zhe-Xiong Lian ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Sorafenib is a kinase inhibitor approved for the treatment of primary kidney cancer, advanced primary liver cancer, and radioactive iodine resistant advanced thyroid carcinoma.